Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Clinical trial NCT06475755 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06475755
- Sponsor
- Tang-Du Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-30
- Primary completion
- 2025-06-10
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.